FindTrial
Sign In

Study of hypofractioned radiotherapyCombined with chemotherapy for treating tracheoesophageal groove lymph node metastasis

Study of hypofractioned radiotherapyCombined with chemotherapy for treating tracheoesophageal groove lymph node metastasis

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1800016848
Enrollment
Unknown
Registered
2018-06-28
Start date
2019-01-01
Completion date
Unknown
Last updated
2018-07-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Esophageal cancer

Interventions

1:Conventional fractioned radiotherapy combined with chemotherapy
2:Hypofractioned radiotherapy combined with chemotherapy

Sponsors

Yancheng Third People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
30 Years to 75 Years

Inclusion criteria

Inclusion criteria: Patients aged less than 75 yrs, with clinical symptoms of hoarseness and bucking, after excluding vocal cord lesions; those who were diagnosed with TGLN metastasis using CT, MRI and/or PET-CT; those without severe cardiovascular diseases (CVDs), renal or splenic dysfunction; and those with an expected survival duration of at least 3 months.

Exclusion criteria

Exclusion criteria: Women of pregnancy and lactation; those complicated with concurrent malignancies; with metastasis in the other organs and/or lymph nodes; those with CRT contraindications; and those with inadequate follow-up data.

Design outcomes

Primary

MeasureTime frame
the overall survival;—

Countries

China

Contacts

Public ContactZhu Haiwen

Yancheng Third People's Hospital

zhuhaiwen163zxm@126.com+86 13951549558

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026